Insphero has raised an eight-figure amount in its latest funding round. InSphero will utilize the proceeds to commercialize its cryo-preservation technology to enable further growth and scalability. ZEISS Ventures is participating in the financing round along with internal and external investors.
InSphero’s comprehensive solutions for preclinical drug safety and efficacy testing are based on 3D microtissues, which are phenotypic models of the smallest functional unit of a tissue or organ. These drug-discovery and testing platforms combine scalable 3D technology, ISO quality-controlled 3D human tissue models, 3D-optimized media, as well as tailored assay services and support. Drug discovery partners immediately gain access to the depth and breadth of InSphero’s experience in developing and applying 3D models for liver toxicology, metabolic diseases and oncology.
“The market for complex 3D in-vitro models is very attractive and is experiencing new tailwinds with the FDA Modernization Act. This Act elevates alternative methods for drug development to the same level as animal testing. InSphero has uniquely positioned itself with its highly industrialized platform solution to address this market opportunity,” says Gerrit Schulte, Head of ZEISS Ventures.
Dr. Jan Lichtenberg, CEO and Co-founder of InSphero, says: “The widespread use of 3D microtissues following the ratification of the FDA Modernization Act requires efficient, automation-compatible, and scalable 3D models quickly. Our ground-breaking, cryopreserved ARCTis 3D Microtissue portfolio offers a storable, always ready-to-use solution to efficient and insightful compound testing. We are on the way to becoming the biggest 3D microtissue biobank in the world.”
ZEISS Ventures is the corporate venture capital arm of the ZEISS Group. Its goal is to enable and accelerate the development and commercialization of market-shaping innovations which are between, beyond, or disruptive to the current ZEISS Strategic Business Units. ZEISS is an internationally leading technology enterprise operating in the optics and optoelectronics industries. The ZEISS Group generated annual revenue totaling more than 8.8 billion euros in its four segments Industrial Quality & Research, Medical Technology, Consumer Markets and Semiconductor Manufacturing Technology.
(Press release / SK)
Please login or sign up to comment.
Commenting guidelines